David Henry Mack - 28 Jun 2021 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
President and CEO, Director
Signature
/s/ David H. Mack
Issuer symbol
PMVP
Transactions as of
28 Jun 2021
Net transactions value
-$7,140
Form type
4
Filing time
29 Jun 2021, 18:09:04 UTC
Previous filing
04 Jun 2021
Next filing
22 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Options Exercise $108 +204 +1.6% $0.5300* 12,674 28 Jun 2021 Direct
transaction PMVP Common Stock Sale $7,248 -204 -1.6% $35.53 12,470 28 Jun 2021 Direct F1
holding PMVP Common Stock 227,915 28 Jun 2021 See footnote F2
holding PMVP Common Stock 56,978 28 Jun 2021 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Stock Option (right to buy) Options Exercise $0 -204 -0.04% $0.000000 474,870 28 Jun 2021 Common Stock 204 $0.5300 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.
F2 The shares are held of record by The Mack-Mulligan Revocable Trust, for which the Reporting Person serves as co-trustee.
F3 The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust, for which the Reporting Person serves as co-trustee.
F4 The shares subject to the option are fully vested and immediately exercisable.